MIRM
MIRM
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
3
$9.12M
Insider Sales
58
$57.40M
Total Volume
$66.52M
100 transactions
Net Activity
$48.28M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 86% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •High accumulation: total purchase value exceeds $1M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
S - Sale+OE Insiders
$540.49B total
Peetz Christopher
CEO
$23.99M total
Grey Michael G
Dir
$11.10M total
Heron Patrick J
Dir
$9.12M total
Howe Jolanda
SVP, GLOBAL CONTROLLER
$8.85M total
Quick Actions
MIRM has an insider buy conviction of 14%, compared to the Unknown sector buy average of 6%. MIRM ranks #229 in insider activity out of 570 tracked companies in its industry.
Over the last 90 days, corporate insiders at MIRM (MIRM) engaged in a total of 100 transactions reported via SEC Form 4 filings. Among these, 3 were open-market purchases and 58 were sales. The total volume of insider trading reached $66.52M.
The net insider activity for MIRM shows a net selling bias of $48.28M. This activity represents a 14% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 4.03M shares valued at $529.86B on Jan 23, 2026.
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
MIRM - Mirum Pharmaceuticals Inc Stock Price and Quote
Mirum Pharmaceuticals (MIRM) Stock May Be About Right As Its 5 Year Run Draws Focus
Is Mirum Pharmaceuticals (MIRM) Undervalued On New Brelo Vitug Trial Data?
An experimental hepatitis D drug met virus and liver targets in 56% of patients; none in the delayed-treatment group did.
How Phase 3 Trial Success At Mirum Pharmaceuticals (MIRM) Has Changed Its Investment Story
FAQs About MIRM Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for MIRM.